Detection of bladder cancer using nuclear matrix protein proteomic marker NMP22.
- Author:
Mesias Cecero U.
;
de la Cruz Reynaldo C.
;
de Guzman Rudolfo I.
- Publication Type:Journal Article
- MeSH: Human; Male; Female; Middle Aged; Neoplasms; Urologic Neoplasms; Urinary Bladder Neoplasms-cytology, diagnosis, pathology; nuclear matrix protein 22; ultrasonography; Tomography Scanners, X-Ray Computed; ;
- From: Philippine Journal of Urology 2011;21(1):9-13
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVE: To determine the validity of NMP-22 (Bladder Check Protein Test Pack Kit) in the diagnosis of bladder cancer.
MATERIALS: From May 1, 2009 to October 31, 2009 all patients with bladder mass by ultrasound, IVP or CT scan from three different urology training institutions were enrolled in this prospective study. These patients underwent urine cytology and NMP-22 qualitative assay. The diagnosis determined from the cytoscopic and histopathologic findings from CTURBT was accepted as the gold standard.
RESULTS: Thirty nine subjects were enrolled in this study, whom of 31 patients were diagnosed of malignancy and 8 were benign in pathology. The sensitivity of urine cytology, NMP-22 assay and cytoscopy was 34.6%, 96.8% and 92.3% respectively and the specificity was 37.5% for NMP-22 and 66.1% for the cytoscopy.
CONCLUSION: The result of this study suggests that NMP-22 is a very sensitive test, however is less specific in identifying bladder cancer.